mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.

Vaccines (Basel) · 2021 · PMC8402682 · PMID 34452043

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Considering the time between first vaccination and analysis, there was a clear trend to increasing SARS-CoV-2-spike-specific T-cell responses in both mRNA vaccination groups ( Figure 6 A,B).

also in 19,460 other papers

highly significantno p-value reported

Multivariate analyses among indicated timepoints revealed a highly significant superiority of both mRNA vaccination groups over not only the reference cohort of COVID-19-convalescent individuals, but also the vector vaccine ChAdOx1-nCoV-19.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.